Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
| Revenue (TTM) | $27.20M |
| Gross Profit (TTM) | $12.00M |
| EBITDA | -129,000 |
| Operating Margin | -8.53% |
| Return on Equity | -8.98% |
| Return on Assets | -4.82% |
| Revenue/Share (TTM) | $15.60 |
| Book Value | $8.25 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | 1.22 |
| EV/Revenue | 1.244 |
| EV/EBITDA | 50.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 24.20% |
| Shares Outstanding | $1.79M |
| Float | $1.41M |
| % Insiders | 12.67% |
| % Institutions | 17.31% |
Volatility is currently expanding
NEW HAVEN, Conn., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2026 shareholder update call on November 10th, 2026, at 5:00 PM ET.
Precipio is an established laboratory services provider in cancer diagnostics and has launched a razor and razor blade model for facilities to test their own samples on site. 16.6% of the stock is held by officers and directors. Vanguard took an initial position, and BlackRock added to its position in Q1 2026. The company is small, and management is thin. It has turned to a distributor model to reach new clients.
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET.
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRPO and any ticker you trade — then tracks every position and per-strategy win rate.
